Preview

Рецепт

Расширенный поиск

Доказательная база применения препаратов альфа-интерферонов при ОРВИ

https://doi.org/10.34883/PI.2021.24.5.006

Полный текст:

Аннотация

В настоящее время клиническая эффективность препаратов рекомбинантных альфа-интерферонов при острых респираторных вирусных инфекциях (ОРВИ) является предметом интенсивных дискуссий медицинских специалистов. Мы проанализировали опубликованные результаты и качество клинических исследований, посвященных оценке клинической эффективности и безопасности препаратов альфа-интерферонов для применения при ОРВИ, и в частности при COVID-19. Показано, что данные лекарственные средства, применяемые интраназально, могут быть эффективны в постконтактной профилактике ОРВИ (прежде всего риновирусной инфекции, в меньшей степени – других ОРВИ, включая сезонный грипп). Интраназальное применение ИФН-α2 также несколько облегчает течение случаев ОРВИ, развившихся на фоне подобной профилактики. Профилактическая и терапевтическая эффективность пре-паратов интерферонов при COVID-19 возможна, однако нуждается в дальнейшем подтверждении в клинических исследованиях. При этом местное применение препаратов ИФН-α2 для профилактики и лечения различных ОРВИ является достаточно безопасным.

Об авторах

И. В. Жильцов
Витебский государственный ордена Дружбы народов медицинский университет
Беларусь

Витебск



С. А. Голубев
СООО «НАТИВИТА»
Беларусь

Минск



А. В. Брухнов
СООО «НАТИВИТА»
Беларусь

Минск



А. С. Шнипов
СООО «НАТИВИТА»
Беларусь

Минск



Список литературы

1. Bandurska K., Król I., Myga-Nowak M. (2014) Interferony: między strukturą a funkcją [Interferons: between structure and function]. Postepy Hig Med Dosw (Online), no 68, pp. 428–40.

2. Fensterl V., Sen G.C. (2009) Interferons and viral infections. Biofactors, no 35 (1), pp. 14–20.

3. Pestka S., Krause C.D., Walter M.R. (2004) Interferons, interferon-like cytokines, and their receptors. Immunol Rev., no 202, pp. 8–32.

4. Lin F.C., Young H.A. (2014) Interferons: Success in anti-viral immunotherapy. Cytokine Growth Factor Rev., no 25 (4), pp. 369–376.

5. Ghosh D., Ghosh D., Parida P. (2016) Physiological Proteins in Therapeutics: A Current Review on Interferons. Mini Rev Med Chem., no 16 (12), pp. 947–52.

6. Weissmann C. (2012) The end of the road. Prion., no 6 (2), pp. 97–104.

7. von Gabain A., Lundgren E., Ohlsson M. (1990) Three human interferon-alpha 2 subvariants disclose structural and functional differences. Eur J Biochem., no 190 (2), pp. 257–61.

8. Kirkwood J.M., Ernstoff M.S. (1984) Interferons in the treatment of human cancer. J Clin Oncol., no 2 (4), pp. 336–52.

9. Chou S. (1984) Advances in antiviral therapy. J Invest Dermatol., no 83 (suppl. 1), pp. 116–120.

10. Berraondo P., Sanmamed M.F., Ochoa M.C. (2019) Cytokines in clinical cancer immunotherapy. Br J Cancer., no 120 (1), pp. 6–15.

11. Kiladjian J.J., Giraudier S., Cassinat B. (2016) Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia, no 30 (4), pp. 776–81.

12. Carithers R.L. Jr., Emerson S.S. (1997) Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology, no 26 (3 suppl. 1), pp. 83–88.

13. Wong J.B., Koff R.S., Tinè F. (1995) Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med., no 122 (9), pp. 664–75.

14. Ascione A., De Luca M., Di Costanzo G.G. (2002) Incidence of side effects during therapy with different types of alpha interferon: a randomised controlled trial comparing recombinant alpha 2b versus leukocyte interferon in the therapy of naive patients with chronic hepatitis C. Curr Pharm Des., no 8 (11), pp. 977–80.

15. Ryff J.C. (1993) To treat or not to treat? The judicious use of interferon-alpha-2a for the treatment of chronic hepatitis B. J Hepatol., no 17, suppl. 3, pp. 42–6.

16. Samuel C.E. (2001) Antiviral actions of interferons. Clin Microbiol Rev., no 14 (4), pp. 778–809.

17. Recommendations (temporary) on the specifics of providing medical care to patients with COVID-19 infection under the age of 18 (approved by order of the Ministry of Health of the Republic of Belarus 30.09.2020 No. 1019; as amended by order of the Ministry of Health of the Republic of Belarus 18.06.2021 No. 715). Available at: https://drive.google.com/file/d/1AKxK6NwI-tk9Jd0XF8fOkmL2SYq7-B30/view (accessed 10 August 2021).

18. Recommendations (temporary) on the organization of medical care for patients with COVID-19 infection (approved by order of the Ministry of Health of the Republic of Belarus No. 900 dated 21.07.2021). Available at: https://bymed.top/docs/by-regulatory/protocols/рекомендации-covid-19-900-1632 (accessed 10 August 2021).

19. Hayden F.G., Albrecht J.K., Kaiser D.L. (1986) Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N Engl J Med., no 314 (2), pp. 71–5.

20. Hayden F.G., Mills S.E., Innes D.J. (1987) Tolerance and nasal histopathologic effects of long-term, low-dose intranasal recombinant interferon alpha-2A (Roferon-A). Antiviral Res., no 8 (3), pp. 139–49.

21. Herzog C., Berger R., Fernex M. (1986) Intranasal interferon (rIFN-alpha A, Ro 22-8181) for contact prophylaxis against common cold: a randomized, doubleblind and placebo-controlled field study. Antiviral Res., no 6 (3), pp. 171–6.

22. Tannock G.A., Gillett S.M., Gillett R.S. (1988) A study of intranasally administered interferon A (rIFN-alpha 2A) for the seasonal prophylaxis of natural viral infections of the upper respiratory tract in healthy volunteers. Epidemiol Infect., no 101 (3), pp. 611–621.

23. Gao L., Yu S., Chen Q. (2010) A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits. Vaccine, no 28 (28), pp. 4445–51.

24. Krasnov V.V. (2019) Influenza and ARVI: the use of recombinant interferon for treatment and prevention in children. Pediatrician practice, no 1, pp. 24–29.

25. Chudakova T.K., Mikhajlova E.V. (2020) The effectiveness of interferon therapy in acute respiratory viral infections in young children. Childhood infections, no 19 (1), pp. 13–16.

26. Petrov V., Tsopa T., Medvedeva T. (2007) The use of interferon alfa-2 in the treatment of acute respiratory viral infections in children. Problems in modern pediatrics, no 6 (6), pp. 101–103.

27. Feklisova L., Gorelov L., Drinevsky V. (2011) The role of interferon medicines in the ARVI treatment in infants and young children (results of a multicenter comparative randomized clinical trial). Pediatric Pharmacology, no 8 (5), pp. 76–82.

28. Abaturov A.E., Agaphonova E.A. (2017) Interferon therapy of acute respiratory viral infections in children. Child health, vol. 12, no 3, pp. 370–375.

29. Gwaltney J.M. Jr., Winther B., Patrie J.T. (2002) Combined antiviral-antimediator treatment for the common cold. J Infect Dis., no 186 (2), pp. 147–54.

30. Chen Q., Zhang L.L., Yu D.X. (2005) A field trial for evaluating the safety of recombinant human interferon alpha-2b for nasal spray. Chinese Journal of Experimental and Clinical Virology, no 19 (3), pp. 211–5.

31. Yu D.X., Chen Q., Zhang L.L. (2005) A field trial of recombinant human interferon alpha-2b for nasal spray to prevent SARS and other respiratory viral infections. Chinese Journal of Experimental and Clinical Virology, no 19 (3), pp. 216–9.

32. Lin H., Huang L., Zhou J. (2016) Efficacy and safety of interferon-α2b spray in the treatment of hand, foot, and mouth disease: a multicenter, randomized, double-blind trial. Arch Virol., no 161 (11), pp. 3073–80.

33. Wiselka M.J., Nicholson K.G., Kent J. (1991) Prophylactic intranasal alpha 2 interferon and viral exacerbations of chronic respiratory disease. Thorax, no 46 (10), pp. 706–11.

34. Tyrrell D.A.J. (1986) The efficacy and tolerance of intranasal interferons: studies at the Common Cold Unit. Journal of Antimicrobial Chemotherapy, vol. 18, suppl. B, pp. 153–156.

35. Hao S.R., Yan R., Zhang S.Y. (2020) Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study. J Zhejiang Univ Sci B., no 21 (8), pp. 628–636.

36. Guo T., Shen Q., Zhou Z. (2020) Combined Interventions for Severe Novel Coronavirus Disease (COVID-19): Experience from 350 Patients. Infect Drug Resist., no 13, pp. 3907–3918.

37. Wang N., Zhan Y., Zhu L. (2020) Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients. Cell Host Microbe, no 28 (3), pp. 455–464.

38. Zhou Q., Chen V., Shannon C.P. (2020) Interferon-α2b Treatment for COVID-19. Front Immunol., no 11, p. 1061.

39. Pereda R., González D., Rivero H.B. (2020) Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience. J Interferon Cytokine Res., no 40 (9), pp. 438–442.

40. Pereda R., González D., Rivero H.B. (2020) Therapeutic Effectiveness of Interferon Alpha 2b Treatment for COVID-19 Patient Recovery. J Interferon Cytokine Res., no 40 (12), pp. 578–588.

41. Zheng F., Zhou Y., Zhou Z. (2020) SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial. Int J Infect Dis., no 99, pp. 84–91.

42. Zhou Q., MacArthur M.R., He X. (2020) Interferon-α2b Treatment for COVID-19 Is Associated with Improvements in Lung Abnormalities. Viruses, no 13 (1), p. 44.

43. Huang Q., Deng X., Li Y. (2020) Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China. Int J Clin Pharm., no 42(3), pp. 837–845.

44. Kim M.S., An M.H., Kim W.J. (2020) Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. PLoS Med., no 17 (12): e1003501.

45. Choupoo N.S., Das S.K., Haldar R. (2020) Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Metaanalysis and Systematic Review of Clinical Trials. Indian J Crit Care Med., no 24 (11), pp. 1106–1113.

46. Nakhlband A., Fakhari A., Azizi H. (2021) Interferon-alpha position in combating with COVID-19: A systematic review. J Med Virol., no 93 (9), pp. 5277–5284.


Для цитирования:


Жильцов И.В., Голубев С.А., Брухнов А.В., Шнипов А.С. Доказательная база применения препаратов альфа-интерферонов при ОРВИ. Рецепт. 2021;(5):663-683. https://doi.org/10.34883/PI.2021.24.5.006

For citation:


Zhiltsov I., Golubev S., Brukhnov A., Shnipov A. Evidence Base for the Use of Alpha-Interferon Preparations for ARVI. Recipe. 2021;(5):663-683. (In Russ.) https://doi.org/10.34883/PI.2021.24.5.006

Просмотров: 29


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1993-4882 (Print)
ISSN 2414-2263 (Online)